Description
IDE034 is an experimental compound currently in early-phase clinical development for advanced solid tumors, including colorectal cancer. Based on the tumor-agnostic trial design, this agent appears to target a molecular pathway relevant across multiple cancer types rather than being specific to colorectal malignancies. The drug is being evaluated in patients with locally advanced or metastatic solid tumors who have progressed on standard therapies.
Mechanism of Action
The specific molecular mechanism of action for IDE034 has not been publicly disclosed in available clinical trial information. Given its tumor-agnostic development approach, the compound likely targets a fundamental cellular pathway involved in cancer cell survival, proliferation, or DNA repair that is dysregulated across various tumor types.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.